m+Medelevator.RU
← Поиск публикаций
Molecular carcinogenesis · 2025

Targeting S1PR1 in Thyroid Cancer: Functional Characterization and Proteasome-Mediated Suppression by Quercetin.

СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Moon Hyunjin, Li Shiying, Hong Yukyung, Ryu Chang Hwan, Ryu Junsun, Baek Seung Joon

Аннотация

Sphingosine-1-phosphate receptor 1 (S1PR1, also known as EDG1) is a G-protein-coupled receptor. Although there have been conflicting results reported, S1PR1 is generally accepted to be protumorigenic in many cancer types. However, S1PR1 has not been studied in thyroid cancer. This study aimed to investigate the biological activity of S1PR1 in thyroid cancer. S1PR1 protein levels were found to be higher in thyroid cancer tissues than adjacent normal tissues. Using an S1PR1-GFP construct, we showed that S1PR1 is localized in the cell membrane; however, when stimulated by sphingosine-1-phosphate, S1PR1 appeared to move inside in the cells. In functional studies, S1PR1 knock-out cells generated using the CRISPR/Cas9 system exhibited reduced S1PR1 activity, including colony formation, cell migration, and cell invasion. This was accompanied by the inhibition of STAT3, ERK1/2, and AKT kinase activity and cell adhesion protein expression. Furthermore, we screened several anticancer compounds to determine their effects on S1PR1 expression levels in thyroid cancer cells and found that quercetin significantly reduced S1PR1 protein levels in these cells. Overall, our results indicated that S1PR1 expression at the protein level has a positive relationship with thyroid cancer progression, as seen in other cancers. These data also suggest that quercetin is a potential anticancer drug that can target S1PR1-positive cells.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты